MDBH

New PatentVest Pulse report reveals how OpenAI's published patent portfolio maps its AI product strategy across conversational AI, AI agents, generative media, developer platforms, personalization, and infrastructure New PatentVest Pulse report reveals how OpenAI's published patent portfolio maps its AI product strategy across conversational AI, AI agents, generative media, developer platforms, personalization, and infrastructure

Dallas, TX, July 02, 2026 (GLOBE NEWSWIRE) -- PatentVest today announced the publication of a new article in its IP Legal Insights section, continuing the firm's commitment to providing practical legal guidance on the technologies and legal developments reshaping intellectual property.

Dallas, TX, June 30, 2026 (GLOBE NEWSWIRE) -- Today, PatentVest, a leading provider of IP Strategy and IP Law services, announced the release of its latest PatentVest Pulse report, "The Crossover: How FGF21 Became the Cardiometabolic Layer Beneath GLP-1."

PatentVest Will Discuss Intellectual Property Strategy, Innovation Intelligence, and the Future of AI-Native IP Services PatentVest Will Discuss Intellectual Property Strategy, Innovation Intelligence, and the Future of AI-Native IP Services

• Analysis of 20 muscle-preservation programs highlights a rapidly emerging category designed to enhance long-term obesity treatment outcomes

Addison, Texas, June 03, 2026 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC (NASDAQ: MDBH) today announced that its CEO & Co-Founder, Chris Marlett, will present live at the Planet MicroCap Las Vegas 2026 conference on Wednesday, June 17, 2026 at 2:00 p.m. ET / 11:00 a.m. PT at the Bellagio Resort & Hotel in Las Vegas, Nevada.

� New case study highlights how PatentVest helped Docana navigate a complex AI patent landscape through freedom-to-operate analysis, competitive intelligence, and strategic IP positioning. · The launch introduces a new Case Studies section on the PatentVest website focused on real-world examples of strategic IP leadership and innovation management.

� Analysis of 27 global triple-agonist programs highlights a rapidly expanding pipeline across major pharmaceutical companies and emerging biotech platforms.

Dallas, TX, April 29, 2026 (GLOBE NEWSWIRE) -- PatentVest today released its latest PatentVest Pulse: “The Last 20%: Retatrutide, the Glucagon Paradox, and the Race to Own Surgery-Level Weight Loss Without Surgery.”